

Investec European and UK ECM Review

September 2024



Executive summary

Global equity market performance robust year to date given an improving macro backdrop – ECM volumes continue to recover although remain below 10-year averages


| 2 | There were a number of drivers behind the summer sell off, including an unwinding of the 'Japanese carry trade' as the BoJ raised rates but at the core of the sell off was concern that the Fed was behind the curve and the US economy was weaker than markets had conditioned for |
|--------|--|
| 3 | Stock markets had largely recovered by the end of August as corporate results and more encouraging economic data helped stabilise sentiment but investors entered into September with expectations of rate cuts building, particularly in the US and EU |
| vestec | Those reductions did come through over the month with the Fed clearly pivoting and cutting by 50bps (taking the Fed Funds rate to 4.75-5%) which has given US equity markets an extra boost and the ECB making its second 25bps cut of this easing cycle (taking the European Deposit rate to 3.5%) |
| 5 | European ECM activity has been relatively robust over the month of September with \$8.1bn of issuance from 38 transactions ⁽¹⁾ – much of that volume has been from secondary offerings and shareholder sell-downs, but the second half of the month has seen the launch (and re-launch) of a number of IPOs including Spinger Nature and Europastry |
| 6 | UK equity markets recovered through August but drifted through September with the FTSE All-Share down -1.4% and the FTSE 250 down -0.2%, with overall sentiment marginally impacted by concerns about the October 30 th Budget and what some see as overly cautious commentary from the new Government |

Equity Market Overview | robust performance YTD


Increasing confidence of 'soft landings' as rate cuts provide support for equity markets

- · Leading global indices have delivered gains across the board year-to-date, with US stocks leading the rally
- US outperformance has been driven primarily by the so-called 'MAG-7', mega-cap technology orientated stocks whose strong performance has been further fuelled by the Artificial Intelligence boom. These 7 stocks have had an outsized impact on the market-cap weighted S&P 500 – its performance on an equal-weighted basis is more moderate (see chart)
- Equity markets experienced heightened volatility in late July and early August as weak economic and employment data sparked fears of a possible US recession, triggering a sharp sell-off in global stocks and a spike in the VIX
- However global equities quickly rebounded with more positive economic data providing confidence that central banks (and in particular the Fed) can manufacture soft landings. The S&P500 and Stoxx600 hit new all-time record highs during September

US equity markets lead the way on returns YTD, but globally equity markets have made progress



In the UK, AIM stocks have underperformed amidst concerns with regard potential IHT reform



Varied sector performance but most have posted gains YTD



Equity Market Overview | valuation disconnect


UK valuations look attractive on a global and historical relative basis


- Since Brexit in 2016, the spread between UK and US equity valuations has increased with further divergence evident since the start of the pandemic and subsequently over the period of UK Government instability
- Index composition does partly explain the divergence the S&P 500's premium-rating is driven by a high concentration of mega-cap technology orientated stocks given their market leadership and (Al influenced) growth prospects
- Private equity and strategic acquirors have recognised the value on offer in UK public equity markets with 33 companies taken private over the past 12 months⁽¹⁾, but there are signs ٠ that public market investors are also starting to act on what they too have recognised for some time

Valuation gap between US and UK equities at its widest in the last 10 years



European equity valuations also trail those in the US but are slightly ahead of the UK






FTSE All-Share STOXX Europe 600

4 Confidential | Investec

Source: FactSet; (1) Refers to completed transactions only; (2) S&P E/W refers to the S&P500 Equal Weighted index

Macro Outlook | improving backdrop


Inflation heading to 2%, a rate cutting cycle underway and growing confidence in economic 'soft landings'



- Inflationary pressures across the globe have eased
- Inflection of interest rate cycle underway, providing a more favourable backdrop for equity markets
- Clarity on UK political outlook driving Sterling strength vs other key global currencies
- Global economy proving resilient despite continued geopolitical uncertainty
- Improving outlook for 'soft-landing', despite recent market jitters



... and clear evidence that the rate cycle has now turned...



...with recent economic data assuaging recession fears...⁽²⁾

5 Confidential | Investec

Soft landing

0%

20%

Source: FactSet; Macrobond; ONS; Investec Economics; BofA European Fund Manager Survey - (1) Global investors' view on the global economy; (2) European investors' view on the European economy


European Equity Issuance 2024 YTD | Overview

European equity issuance remains well below 10-year averages, but YoY improvements and positive aftermarket performances provide for optimism


ECM activity steadily recovering given the improving backdrop

| Deal Value (US\$bn) | 2022 | % Total | 2023 | % Total | 2024 | % Total | 2024 vs. 2023 |
|---------------------|------|---------|------|---------|------|---------|---------------|
| Follow-Ons | 18 | 26% | 19 | 23% | 14 | 16% | 0.7x |
| Sell-downs | 20 | 28% | 35 | 41% | 41 | 46% | 1.2x |
| IPOs | 14 | 21% | 8 | 10% | 14 | 16% | 1.7x |
| Rights Issues | 13 | 19% | 11 | 13% | 15 | 16% | 1.3x |
| Convertibles | 4 | 5% | 11 | 13% | 6 | 6% | 0.5x |
| Total | 70 | | 84 | | 90 | | 1.1x |
| No. Value | 2022 | % Total | 2023 | % Total | 2024 | % Total | 2024 vs. 2023 |
| Follow-Ons | 93 | 39% | 79 | 33% | 68 | 28% | 0.9x |
| Sell-downs | 70 | 29% | 72 | 30% | 99 | 40% | 1.4x |
| IPOs | 30 | 13% | 30 | 13% | 36 | 15% | 1.2x |
| Rights Issues | 35 | 15% | 33 | 14% | 28 | 11% | 0.8x |
| Convertibles | 11 | 5% | 23 | 10% | 16 | 6% | 0.7x |
| Total | 239 | | 237 | | 247 | | 1.0x |


ECM volumes (inc. UK) continue recovery from '22 low but still below 10- year averages



Growing ECM activity in the seasonally key periods



Successful LSEG and Haleon sell-downs driven FIG and Consumer YTD volumes



6 Confidential | Investec

Source: Dealogic. Analysis and commentary only includes transactions greater or equal to \$US50m. References to European ECM include the UK and exclude Middle East and Africa. Includes Investment Funds. Charts show year-to-date activity levels

European IPO Issuance 2024 YTD | Improving Outlook

IPO volumes remain subdued across Europe relative to 10-year averages, however volumes are up YoY and successfully completed transactions across the region have generally performed well

IPO issuance in Europe


- US\$14bn raised across 36 transactions so far in 2024, up by 72% and 20% respectively versus the \$8bn raised across 30 deals in 2023 YTD
- Average IPO size so far this year of US\$398m vs. US\$278m last YTD
- Average YTD post-IPO share price gain of c.16%. 22 transactions out of 36
 have delivered positive after-market returns for shareholders
- · Consumer sector been busiest this year, raising US\$4bn over 4 IPOs
- There have been three deals over US\$2bn this year: Spanish fashion company Puig Brands (US\$2.4bn); prescription drug and aesthetic solutions provider Galderma (US\$2.6bn) and private equity firm CVC (US\$2.5bn)
- August and September saw no deals over US\$50m, with the average deal size being US\$27m and US\$16m respectively
- As we enter Q4 2024, we remain cautiously optimistic on the outlook for European and UK IPOs. Global equity markets continue to attract capital, and equity market performance has been robust so far this year. Additionally, we think this summer's FCA Listing Rule reforms will serve as helpful tailwinds for UK IPOs
- Market will continue taking cues from growth- orientated macro-data releases
 against a reducing-rate backdrop
- Clarity over the domestic budget in October should support an up-tick in UK issuance activity


European (inc. UK) IPO activity is sitting well below the 10-year average...



| Date | Company | Sector | Country | Deal Value (US\$m) | IPO Mcap (£m) | % Co. Sold | Prim. / Sec. (%) | Post- IPO return | |
|--------|----------------------|-------------|-------------|--------------------|---------------|------------|------------------|------------------|-----|
| 12 Jul | Promomed Group | Healthcare | Russia | 58 | 958 | 6% | 100 / 0 | 0.0% | |
| 09 Jul | Rosebank Industries | FIG | UK | 64 | 64 | 100% | 100 / 0 | 143.0% | ⊕lr |
|)5 Jul | Vseinstrumenti RU | ТМТ | Russia | 136 | 1,132 | 12% | 0 / 100 | 0.0% | |
| 24 Jun | Paratus Energy | Oil & Gas | Norway | 75 | 829 | 9% | 100 / 0 | 4.6% | |
| 20 Jun | Cinclus Pharma | Healthcare | Sweden | 68 | 180 | 38% | 100 / 0 | (33.3%) | |
| 18 Jun | Prisma Properties | Real Estate | Sweden | 150 | 412 | 36% | 80 / 20 | (3.7%) | |
| 11 Jun | Raspberry Pi | TMT | UK | 228 | 690 | 33% | 19 / 81 | 39.0% | |
|)7 Jun | Exosens SAS | TMT | France | 437 | 1,844 | 24% | 51 / 49 | 1.9% | |
|)3 Jun | Yigit Aku | TMT | Turkey | 81 | 324 | 25% | 67 / 33 | 19.7% | |
| 30 Apr | Puig Brands | Consumer | Spain | 2,936 | 14,441 | 20% | 48 / 52 | (15.9%) | |
| 26 Apr | CVC Capital Partners | FIG | Netherlands | 2,451 | 14,998 | 16% | 12 / 88 | 44.9% | |
| 21 Mar | Galderma | Healthcare | Swiss | 2,561 | 14,124 | 18% | 99 / 1 | 50.9% | |
| 19 Mar | Douglas | Consumer | Germany | 966 | 3,041 | 32% | 96 / 4 | (20.6%) | |
| | Average | | | 785 | 4,080 | 28 | 67 / 33 | 17.7% | |

... and the same can be said for the UK IPO issuance levels






Source: Dealogic. Analysis and commentary only includes transactions greater or equal to \$US50m. References to European ECM include the UK and exclude Middle East and Africa. Includes Investment Funds. Charts show year-to-date activity levels

UK ECM activity | September

UK ECM issuance picked up in September after the usual summer slowdown, with shareholder sell-downs continuing to dominate amidst CGT uncertainty




2024 UK ECM YTD activity vs 2023 snapshot

| | 2024 YTD | 2023 YTD | Variance | | |
|----------------------------|-------------|-------------|----------|--|--|
| Total funds raised (£m) | 20,942 | 15,398 | +36.0% | | |
| Total no. transactions | 105 | 93 | +12.9% | | |

Comparison: UK ECM activity in September 2023





Funds raised Deal count Largest primary Largest secondary £3,439m 10 deals EVERN £993m 2993m 22,027m Sell-down In the Market and Rumoured UK IPOs




8 Confidential | Investec


Source: Dealogic; (1) Analysis and commentary only includes transactions greater or equal to £5m; (2) Analysis and commentary only includes transactions greater or equal to \$US50m - chart above show year-to-date activity levels; IFR ECM

2025 Equity Issuance | Primed for Recovery

Strong secondary market performance a precursor to a recovery in ECM volumes and very important for IPO activity



IPO activity rebounded in 2004, 2010 and 2021 following a robust recovery in equity markets



9 Confidential | Investec


Source: Dealogic. Analysis and commentary only includes transactions greater or equal to \$US50m. References to European ECM include the UK and exclude Middle East and Africa. Includes Investment Funds. Charts show year-to-date activity levels

UK Funds Flow Overview | Perceptions changing


Despite a challenging funds flow environment for UK equities since 2021, there are signs of improvement

- Flow at the aggerate level still looks mildly down but anecdotal evidence suggests that several funds have had positive flows since Q2 2024
- Several institutions including the likes of Janus Henderson, Artemis, JO Hambro, and TT have had inflows into their European / UK equity funds
- US Investors continue to make up an increasing % of Investec's trading commissions although has plateaued very recently as some are now looking for further clarity from the UK Budget

Investec's trading commission from US clients since 2023




UK mutual fund outflows remain challenging, but picture improving...^{(1)}



 \ldots and FTSE 250 ETF AuM has been growing through 2024...^{(2)}



...whilst investor perceptions are that UK equities are back in vogue⁽³⁾ ...




10 Confidential | Investec

Source: (1) Calastone - fund flow data relates to UK mutual funds only; Bloomberg; (2) Chart shows increasing share count of Vanguard FTSE 250; (3) BofA European Fund Manager Survey

UK Public M&A activity | September

UK public market valuations continue to attract significant interest from trade and private capital



11 Confidential | Investec

Source: Company announcements; FactSet; Practical Law

Note: Scorecard includes competing offers and withdrawn of companies subject to the Takeover Code quoted on AIM or the Main Market. Formal sales processes are not included unless a buyer has been identified. Only newly announced offers in the month are included in the count (i.e. possible offers announced in December 2023 will be included in that month even if it becomes a firm offer in January 2024)



Senior-led team | significant hands-on experience

An experienced and well-established team

Jonathan Arrowsmith **Carlton Nelson Investment Banking & Equities** Head of Investment Banking Head of UK Corporate **Broking & PLC Advisory** 25+ vears(1) 20 years 4 🔊 Equity Capital Markets & PLC Advisory (UK & Frontier Markets) M&A Advisory, Private Equity Origination and Capital Fundraising < **F** < 🕥 **Duncan Smith Ben Griffiths Jarret Geldenhuys** Ashleigh Williams Luke Spells Kate Gribbon **Oliver Andrews** Head of UK Director. Managing Director, Director. Head of Head of UK Private **Director. UK Private UK ECM FM ECM** ECM **FM ECM** M&A Advisory **Equity Coverage Capital Fundraising** 25+ years 10 years 25+ years 10 years 20+ years 20 years 10 years Equities, Sales and Research (UK) Equity Sales (UK & International)



Clive Murray

Head of Equities 25+ years



Head of UK Sales Desk



4 S Paul Divito

25+ years

Andrew Whitney Head of UK

Research

20+ years



Adam Bidwell



Callum Hillicks

European

Equity Sales

10 years



US **Equity Sales** 20+ years



Andrew Schultz

Head of Frontier Market Sales 25+ years

12 Confidential | Investec Notes: (1) Denotes years of industry experience

Out of the Ordinary since 1974

[⊕]Investec

This document and any attachments (including any e-mail that accompanies it) (together, "this document") is for general information only and is the property of Investec Bank plc ("Investec"). Investec is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. Investec is registered in England and Wales (Reg. no. 489604) with its registered office at 30 Gresham Street, London EC2V 7QP. Whilst all reasonable care has been taken to ensure that the information stated herein is accurate and opinions fair and reasonable, neither Investec nor any of its affiliates or subsidiaries or any of its or their directors, officers, employees or agents ("Affiliates") shall be held responsible in any way for the contents of this document. This document is produced solely for your information and may not be copied, reproduced, further distributed (in whole or in part) to any other person or published (in whole or in part) for any purpose without the prior written consent of Investec. Making this document available in no circumstances whatsoever implies the existence of an offer or commitment or contract with Investec or any of its Affiliates for any purpose.

No representation or warranty, express or implied, is or will be made and no responsibility or liability is or will be accepted by Investec or its Affiliates in relation to the accuracy, reliability, suitability or completeness of any information contained in this document and any such liability is expressly disclaimed. This document does not purport to be all inclusive or to contain all the information that you may need. Investec gives no undertaking to provide the recipient with access to any additional information or to update this document or any additional information, or to correct any inaccuracies in it which may become apparent. This document does not take into account the specific investment objectives, financial circumstances or particular needs of any recipient and it should not be regarded as a substitute for the exercise of the recipient's own judgement and due diligence. Investec does not offer investment advice. Recipients of this document should seek independent financial advice regarding the appropriateness or otherwise of investing in any investment strategies discussed or recommended in this document and should understand that past performance is not a guide to future performance, and the value of any investments may fall as well as rise.

Investec expressly reserves the right, without giving reasons therefore, at any time and in any respect, to amend or terminate discussions with the recipient of this document without prior notice and hereby expressly disclaims any liability for any losses, costs or expenses incurred by such recipient.

